Apellis Pharmaceuticals (APLS) Now Covered by Evercore ISI
A number of other equities research analysts have also recently issued reports on APLS. J P Morgan Chase & Co assumed coverage on Apellis Pharmaceuticals in a report on Monday. They set an “overweight” rating and a $31.00 price objective for the company. Citigroup assumed coverage on Apellis Pharmaceuticals in a report on Monday. They set a “buy” rating and a $23.00 price objective for the company.
Shares of Apellis Pharmaceuticals (NASDAQ:APLS) opened at $13.73 on Monday. Apellis Pharmaceuticals has a 1-year low of $12.45 and a 1-year high of $15.41.
In other news, major shareholder Global Strategic Fund I. Venbio acquired 127,515 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, November 13th. The stock was bought at an average price of $14.00 per share, for a total transaction of $1,785,210.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
TRADEMARK VIOLATION NOTICE: This article was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://theolympiareport.com/2017/12/06/apellis-pharmaceuticals-apls-now-covered-by-evercore-isi.html.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.
Receive News & Ratings for Apellis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.